Compare Stocks: VANI, COCH, BIOA, and OVID

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIOA BioAge Labs	$11.27 +2.6%	$20.16	$4.25 ▼ $25.95	$488.09M	0.93	1.33 million shs	843,407 shs
COCH Envoy Medical	$0.68 -0.5%	$0.69	$0.36 ▼ $1.89	$52.59M	1.9	332,649 shs	30,170 shs
OVID Ovid Therapeutics	$2.65 +1.1%	$2.45	$0.50 ▼ $3.11	$489M	0.21	1.55 million shs	1.29 million shs
VANI Vivani Medical	$1.36 -1.4%	$1.28	$0.92 ▼ $1.92	$119.00M	2.35	329,884 shs	52,451 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIOA BioAge Labs	-1.96%	-50.52%	-55.80%	-38.38%	+147.30%
COCH Envoy Medical	-0.60%	+6.33%	-14.03%	+3.64%	-53.78%
OVID Ovid Therapeutics	+3.15%	+14.41%	+0.38%	-4.03%	+427.91%
VANI Vivani Medical	-1.43%	+9.52%	+6.15%	+14.05%	-8.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIOA BioAge Labs	$11.27 +2.6%	$20.16	$4.25 ▼ $25.95	$488.09M	0.93	1.33 million shs	843,407 shs
COCH Envoy Medical	$0.68 -0.5%	$0.69	$0.36 ▼ $1.89	$52.59M	1.9	332,649 shs	30,170 shs
OVID Ovid Therapeutics	$2.65 +1.1%	$2.45	$0.50 ▼ $3.11	$489M	0.21	1.55 million shs	1.29 million shs
VANI Vivani Medical	$1.36 -1.4%	$1.28	$0.92 ▼ $1.92	$119.00M	2.35	329,884 shs	52,451 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIOA BioAge Labs	-1.96%	-50.52%	-55.80%	-38.38%	+147.30%
COCH Envoy Medical	-0.60%	+6.33%	-14.03%	+3.64%	-53.78%
OVID Ovid Therapeutics	+3.15%	+14.41%	+0.38%	-4.03%	+427.91%
VANI Vivani Medical	-1.43%	+9.52%	+6.15%	+14.05%	-8.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIOA BioAge Labs	2.71	Moderate Buy	$36.57	224.50% Upside
COCH Envoy Medical	2.00	Hold	$2.25	230.49% Upside
OVID Ovid Therapeutics	2.89	Moderate Buy	$5.38	102.83% Upside
VANI Vivani Medical	2.25	Hold	$3.75	175.74% Upside

Current Analyst Ratings Breakdown

Latest VANI, COCH, BIOA, and OVID Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	BIOA BioAge Labs	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
8/3/2026	OVID Ovid Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$7.00 ➝ $9.00
7/31/2026	BIOA BioAge Labs	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
7/31/2026	BIOA BioAge Labs	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00
7/31/2026	BIOA BioAge Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$50.00 ➝ $35.00
7/27/2026	COCH Envoy Medical	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$2.00
7/21/2026	BIOA BioAge Labs	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/21/2026	COCH Envoy Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/21/2026	OVID Ovid Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	OVID Ovid Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	COCH Envoy Medical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.50

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIOA BioAge Labs	$8.99M	55.72	N/A	N/A	$7.59 per share	1.48
COCH Envoy Medical	$240K	218.08	N/A	N/A	($0.42) per share	-1.62
OVID Ovid Therapeutics	$7.25M	68.22	N/A	N/A	$1.00 per share	2.65
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIOA BioAge Labs	-$80.61M	-$2.40	N/A	N/A	N/A	-912.26%	-30.52%	-28.41%	N/A
COCH Envoy Medical	-$23.76M	-$1.01	N/A	N/A	N/A	-9,875.64%	N/A	-177.92%	8/6/2026 (Estimated)
OVID Ovid Therapeutics	-$17.41M	-$0.29	N/A	N/A	N/A	-240.11%	-22.51%	-18.67%	8/12/2026 (Estimated)
VANI Vivani Medical	-$26.61M	-$0.40	N/A	N/A	N/A	N/A	-264.04%	-79.85%	8/12/2026 (Estimated)

Latest VANI, COCH, BIOA, and OVID Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	OVID Ovid Therapeutics	-$0.10	N/A	N/A	N/A	$0.02 million	N/A
8/12/2026	Q2 2026	VANI Vivani Medical	-$0.08	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	COCH Envoy Medical	-$0.09	N/A	N/A	N/A	$0.05 million	N/A
8/5/2026	Q2 2026	BIOA BioAge Labs	-$0.65	-$0.58	+$0.07	-$0.58	N/A	$2.45 million
5/13/2026	Q1 2026	VANI Vivani Medical	-$0.08	-$0.08	N/A	-$0.08	N/A	N/A
5/12/2026	Q1 2026	OVID Ovid Therapeutics	-$0.12	-$0.12	N/A	-$0.12	$0.06 million	N/A
5/11/2026	Q1 2026	COCH Envoy Medical	-$0.14	-$0.11	+$0.03	-$0.08	$0.10 million	$0.04 million
5/8/2026	Q1 2026	BIOA BioAge Labs	-$0.71	-$0.52	+$0.19	-$0.52	N/A	$2.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIOA BioAge Labs	N/A	N/A	N/A	N/A	N/A
COCH Envoy Medical	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIOA BioAge Labs	N/A	24.76	24.76
COCH Envoy Medical	N/A	2.27	2.14
OVID Ovid Therapeutics	0.06	10.17	10.17
VANI Vivani Medical	N/A	3.18	3.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIOA BioAge Labs	N/A
COCH Envoy Medical	8.59%
OVID Ovid Therapeutics	72.24%
VANI Vivani Medical	6.78%

Insider Ownership

Company	Insider Ownership
BIOA BioAge Labs	17.55%
COCH Envoy Medical	7.10%
OVID Ovid Therapeutics	7.00%
VANI Vivani Medical	53.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIOA BioAge Labs	N/A	44.45 million	36.65 million	N/A
COCH Envoy Medical	34	76.88 million	71.42 million	Not Optionable
OVID Ovid Therapeutics	60	186.64 million	173.58 million	Optionable
VANI Vivani Medical	20	86.24 million	40.27 million	Optionable

VANI, COCH, BIOA, and OVID Headlines

Recent News About These Companies

Vivani Medical Completes Enrollment, Dosing in Phase 1 SLIM-1 Trial

August 6 at 3:31 PM | finance.yahoo.com

ClearOne (CLRO) stock soars over 98% after hours: Here's what you need to know

August 6 at 9:17 AM | msn.com

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic ...

August 6 at 9:17 AM | finance.yahoo.com

Vivani Completes Enrollment in SLIM-1 Semaglutide Implant Trial

August 6 at 9:11 AM | tipranks.com

Vivani Medical (VANI) to Announce Earnings on Wednesday

August 5 at 9:40 AM | marketbeat.com

Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal

July 15, 2026 | marketbeat.com

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

July 14, 2026 | globenewswire.com

Next Frontier In Weight Loss? New Implant Looks To Lock In GLP-1 Results

July 14, 2026 | msn.com

The next GLP-1 bet? Implant draws Novo interest

July 13, 2026 | beckershospitalreview.comB

Vivani Medical

July 13, 2026 | fool.com

Weight-loss implant could one day replace Ozempic injections

July 12, 2026 | msn.com

Analysts Set Expectations for Vivani Medical Q1 Earnings

July 10, 2026 | marketbeat.com

Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal

July 9, 2026 | finance.yahoo.com

Vivani Medical signs agreement with Novo Nordisk to evaluate NPM-139

July 9, 2026 | pharmabiz.comP

Ozempic & Wegovy maker to evaluate long-acting GLP-1 implant that could last up to a year

July 9, 2026 | msn.com

Novo Nordisk pens long-acting GLP-1 implant tech deal with Vivani Medical

July 7, 2026 | fiercebiotech.comF

Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant

July 7, 2026 | finance.yahoo.com

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

July 7, 2026 | globenewswire.com

Vivani strikes reverse-merger agreement with ClearOne for BCI business

July 3, 2026 | finance.yahoo.com

ClearOne to Merge With Vivani Medical Subsidiary Cortigent

July 2, 2026 | marketwatch.com

Vivani to sell neurotech subsidiary Cortigent to ClearOne

July 2, 2026 | massdevice.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI, COCH, BIOA, and OVID Company Descriptions

BioAge Labs NASDAQ:BIOA

$11.27 +0.29 (+2.64%)

Closing price 04:00 PM Eastern

Extended Trading

$11.24 -0.04 (-0.31%)

As of 06:43 PM Eastern

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Envoy Medical NASDAQ:COCH

$0.68 0.00 (-0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$0.67 -0.01 (-1.44%)

As of 06:42 PM Eastern

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

Ovid Therapeutics NASDAQ:OVID

$2.65 +0.03 (+1.15%)

Closing price 04:00 PM Eastern

Extended Trading

$2.57 -0.08 (-2.98%)

As of 06:43 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Vivani Medical NASDAQ:VANI

$1.36 -0.02 (-1.45%)

Closing price 04:00 PM Eastern

Extended Trading

$1.39 +0.03 (+2.21%)

As of 06:12 PM Eastern

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VANI, COCH, BIOA, and OVID Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VANI, COCH, BIOA, and OVID Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VANI, COCH, BIOA, and OVID Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI, COCH, BIOA, and OVID Company Descriptions

BioAge Labs NASDAQ:BIOA

Envoy Medical NASDAQ:COCH

Ovid Therapeutics NASDAQ:OVID

Vivani Medical NASDAQ:VANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VANI, COCH, BIOA, and OVID Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VANI, COCH, BIOA, and OVID Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VANI, COCH, BIOA, and OVID Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI, COCH, BIOA, and OVID Company Descriptions

BioAge Labs NASDAQ:BIOA

Envoy Medical NASDAQ:COCH

Ovid Therapeutics NASDAQ:OVID

Vivani Medical NASDAQ:VANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools